Home Online Features Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Press Releases
Palatin Technologies, Inc.  
October 31, 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Topline results expected in 1Q calendar year 2025Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weightData will inform and support the Company's obesity programs using novel,

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social